EVFM Evofem Biosciences
- 0.013
- -0.001-6.47%
Evofem Biosciences News
Evofem Strengthens Phexxi Intellectual Property With New Composition of Matter Patent From USPTO
-- Application allowed with broad method claims that are Orange Book-listable -- -- Once issued, this will be Evofem's fifth patent covering Hormone-Free "In the Moment" Contraceptive Phexxi in the U
Evofem Biosciences Issues Update With Latest Presentation
Evofem Biosciences 4Q Loss/Shr 44c >EVFM
Evofem Biosciences 4Q Loss/Shr 44c >EVFM
Evofem Reports $18.2 Million of Phexxi Net Product Sales in 2023
-- Third Consecutive Year of Phexxi Net Sales Growth -- -- Total Operating Expense Reduced 64% from 2022 Levels -- -- Sales and marketing expense as a percentage of net sales was 54% for the fourth q
Press Release: Evofem Negotiates Improved Rebate for Hormone-Free "In the Moment" Contraceptive PHEXXI With Medi-Cal
Evofem Negotiates Improved Rebate for Hormone-Free "In the Moment" Contraceptive PHEXXI with Medi-Cal PR Newswire SAN DIEGO, March 20, 2024 -- Medi-Cal serves more than 15.4 million Californians --
For Women Using GLP-1 Receptor Agonists Who Take Oral Birth Control Pills, Hormone-Free Phexxi Contraceptive Gel Is a Logical Solution to Help Prevent Unintended Pregnancy
Express News | 'France Becomes First Country to Explicitly Enshrine Abortion Rights in Constitution' -Washington Post Report
Evofem Biosciences Achieves 2023 Prelim Net Product Sales of $18.1M to $18.3M
Evofem Biosciences Announces Strong Preliminary Results, Record Phexxi Net Sales for Fiscal 2023
Evofem Biosciences(EVFM.US) Officer Sells US$4 in Common Stocks
$Evofem Biosciences(EVFM.US)$ Officer Zhang Yan sold 104 shares of Common Stocks on Jan 12, 2024 at an average price of $0.0385 for a total value of $4.Source: Announcement What is statement of change
Washington State HCA Removes Prior Authorization for Hormone-Free "In the Moment" Contraceptive PHEXXI Ahead of Huskies Vs. Wolverines Championship Game
Laidlaw & Co. Downgrades Evofem Biosciences to Hold
Laidlaw & Co. analyst Yale Jen downgrades Evofem Biosciences (OTC:EVFM) from Buy to Hold.
Evofem Biosciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 12/13/2023 — Laidlaw & Co. Downgrades Buy → Hold 10/13/2022 426.32% Stifel $3 → $0.5 Downgrades Buy → Hol
Shareholder Alert: Ademi LLP Investigates Whether Evofem Biosciences, Inc. Has Obtained a Fair Price in Its Transaction With Aditxt
MILWAUKEE, Dec. 12, 2023 /PRNewswire/ -- Ademi LLP is investigating Evofem (OTCQB: EVFM) for possible breaches of fiduciary duty and other violations of law in its transaction with Aditxt. Click here
Shares of Aditxt, Evofem Surge on $100 Million Acquisition Deal
By Dean Seal Shares of Aditxt and Evofem Biosciences soared after the companies signed a $100 million acquisition deal. Aditxt's stock was up 85% at $7.03 in premarket trading, after having closed t
Aditxt to Acquire Women's Health Company Evofem Biosciences
Aditxt To Acquire Evofem in Consideration of the Issuance of a Combination of Common Stk and Preferred Stk, and the Assumption of Certain Senior Indebtedness, Having an Aggregate Amount of $100M >ADTX
Aditxt To Acquire Evofem in Consideration of the Issuance of a Combination of Common Stk and Preferred Stk, and the Assumption of Certain Senior Indebtedness, Having an Aggregate Amount of $100M >ADTX
Aditxt Looks to Accelerate Evofem Into the Global Non-Hormonal Birth Control Market >ADTX
Aditxt Looks to Accelerate Evofem Into the Global Non-Hormonal Birth Control Market >ADTX
Aditxt, Inc. Enters Into Definitive Agreement To Acquire Evofem Biosciences, Inc., Creator Of Phexxi(R), The First And Only FDA-Approved Hormone-Free Contraceptive Gel, To Address Diverse Reproductive Health Needs Of Women Globally >ADTX
Aditxt, Inc. Enters Into Definitive Agreement To Acquire Evofem Biosciences, Inc., Creator Of Phexxi(R), The First And Only FDA-Approved Hormone-Free Contraceptive Gel, To Address Diverse Reproductive
Evofem Biosciences GAAP EPS of $0.10, Revenue of $5.11M
Analysis
Price Target
No Data
